Clinical study on effect of Xiaoyao Nose Drops in stopping episode of migraine.
OBJECTIVE
To observe the effect of Xiaoyao Nose Drops (XYND) in stopping episode of migraine.


METHODS
Adopted was the randomized double-blinded placebo-controled method, with the 126 patients equally assigned to two groups, the treated group treated with XYND and the control group with placebo, and the therapeutic course was 30 days for all. The clinical total effective rate and effect in alleviating headache were observed. And hemorrheological parameters as well as the blood flow of the anterior cerebral artery (ACA), median cerebral artery (MCA) and posterior cerebral artery (PCA) were measured before and after treatment.


RESULTS
The clinical total effective rate and headache alleviating rate in the treated group were 93.33% and 96.67% respectively, while those in the control group were 18.33% and 20.00% respectively, and comparison between the two groups showed significant difference (all P < 0.01). The blood viscosity (high, middle and low shear), plasma viscosity and fibrinogen got lowered significantly in the treated group after treatment, showing significant difference in comparison either with those before treatment or with those in the control group after treatment (P < 0.05 or P < 0.01). The velocity of blood flow in all cerebral arteries lowered significantly, also showing significant difference in comparison either with those before treatment or with those in the control group after treatment (P < 0.05 or P < 0.01).


CONCLUSIONS
XYND is effective in stopping the headache of patients with migraine, and worth applying in clinical practice.
Hu
Huai-qiang
HQ
Shandong University of TCM, Jinan 250014, China. huhaiqiang@126.com
Zhou
Yong-hong
YH
Wang
Xin-lu
XL
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000368:Aged; D001783:Blood Flow Velocity / Q000187:drug effects; D001809:Blood Viscosity / Q000187:drug effects; D002560:Cerebrovascular Circulation / Q000187:drug effects; D004311:Double-Blind Method; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*
D004365:Drugs, Chinese Herbal; C516449:xiaoyao; D005340:Fibrinogen